Natera Q3 revenue $268.3M (+27% YoY), raises FY2023 revenue and margin guidance, reduces cash burn

Natera, Inc.

2023-Q3 EPS reported -$3.14 revenue$771,466,000

Revenue $268.3M, up 27% YoY; product revenue $265.2M, up 33% YoY.
Processed ~626,000 tests (+21% YoY); oncology tests ~89,000 (+68% YoY) with 81,000 Signatera clinical units (+85%).
Net loss improved to $109.0M ($0.95/share) from $121.5M ($1.25/share) in Q3 2022.
Raises 2023 revenue guidance to $1.035B-$1.05B (from $1.015B-$1.035B); cash burn reduced to $260M-$280M (from $300M-$325M).
Cash, equivalents and investments $936.6M; total debt $363.0M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Natera, Inc. reported third quarter ended September 30, 2023 results: revenue $268.3 million, net income net loss of $109.0 million, EPS ($0.95) per diluted share. Guidance raised.

Period: third quarter ended September 30, 2023
Revenue: $268.3 million
Net income: net loss of $109.0 million
EPS: ($0.95) per diluted share
Guidance: raised
Result: reported results

Exact text from the filing

cell-free DNA testing , today reported financial results for the third quarter ended September 30, 2023. Recent Strategic and Financial Highlights ● Generated total revenues of $268.3 million in the third quarter of 2023, compared to $210.6 million in the third quarter of 2022, an increase of approximately 27%. Product revenues grew approximately 33% over the same

View on SEC.gov

Browse all earnings releases →

Natera, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-115735

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.